Loading…
Sickle Cell Disease Comprehensive Care Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
69pct
10d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2024 · second_quarter · Medicare/Medicaid
Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Implementation of the Hemophilia SNF Access Act Coverage for Telehealth Services Closing the Medicaid coverage gap Issues related to 1115 Waivers in Medicaid Medicaid unwinding, the process for redetermination of Medicaid eligibility Preserving and expanding access to Medicaid Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) PROTECT Rare Act (H.R. 6094) MVP Act (H.R. 2666)
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2024 · second_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare Hospice Benefit Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act pf 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues impacting opioid access/use for patients with hematologic disease and disorders Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Strengthening Medicare for Patients and Providers Act (H.R. 2474) Resident Physician Shortage Reduction Act (S. 1302) CONNECT for Health Act (S. 2016/ H.R. 4189) Improving Access to Transfusion Care for Hospice Patients Act (S. 2186) Provider Reimbursement Stability Act of 2023 (H.R. 6371) Telehealth Modernization Act (H.R. 7623 / S. 3967) Sickle Cell Disease Comprehensive Care Act (H.R. 7432) dental coverage for Medicare beneficiaries Centers for Medicare & Medicaid Services (CMS) FY 2025 Hospice proposed rule request for information on payment mechanisms for high intensity palliative care services, including blood transfusions Improving Seniors' Timely Access to Care Act (S. 4518/S. 4532/H.R. 8702) Senate Finance Committee Request for Information (RFI) on Medicare Graduate Medical Education (GME) and physician workforce shortages Senate Finance Committee Request for Information (RFI) on Medicare physician payment National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Duffy-null ICD-10 coding Issues impacting drug shortages
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Comprehensive Care Act (H.R. 7432) H.Res. 1180, re: diversity, equity and inclusion in medical education
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2024 · first_quarter · Medicare/Medicaid
Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Implementation of the Hemophilia SNF Access Act Coverage for Telehealth Services Closing the Medicaid coverage gap Issues related to 1115 Waivers in Medicaid Medicaid unwinding, the process for redetermination of Medicaid eligibility Preserving and expanding access to Medicaid Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) PROTECT Rare Act (H.R. 6094) MVP Act (H.R. 2666) Comments Re: Medicaid; CMS Enforcement of State Compliance with Reporting and Federal Medicaid Renewal Requirements Under Section 1902(t) of the Social Security Act (CMS-2447-IFC) Comments RE: Notice of Benefit and Payment Parameters for 2025 Proposed Rule (CMS-9895-P). Comments Re: Proposed Rescission of Association Health Plan Final Rule (RIN 1210-AC16)
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2024 · first_quarter · Medicare/Medicaid
Engagement with the Center for Medicare and Medicaid Innovation on the Cell & Gene Therapy Access Model Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) Sickle Cell Disease Comprehensive Care Act (H.R. 7432) CMSs Office of Minority Health Sickle Cell Disease Action Plan
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · first_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare Hospice Benefit Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act pf 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues impacting opioid access/use for patients with hematologic disease and disorders Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Strengthening Medicare for Patients and Providers Act (H.R. 2474) Resident Physician Shortage Reduction Act (S. 1302) CONNECT for Health Act (S. 2016/ H.R. 4189) Improving Access to Transfusion Care for Hospice Patients Act (S. 2186) Provider Reimbursement Stability Act of 2023 (H.R. 6371) Telehealth Modernization Act (H.R. 7623 / S. 3967) Sickle Cell Disease Comprehensive Care Act (H.R. 7432) National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS dental coverage for Medicare beneficiaries
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · first_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746) Sickle Cell Disease Comprehensive Care Act (H.R. 7432)
Client expense: $30,000 · Firm income: Not reported
2023 · fourth_quarter · Health Issues
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
Engagement with the Center for Medicare and Medicaid Innovation on the Cell & Gene Therapy Access Model Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) CMSs Office of Minority Health Sickle Cell Disease Action Plan
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · fourth_quarter · Medicare/Medicaid
Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Implementation of the Hemophilia SNF Access Act Coverage for Telehealth Services Closing the Medicaid coverage gap Issues related to 1115 Waivers in Medicaid Medicaid unwinding, the process for redetermination of Medicaid eligibility Preserving and expanding access to Medicaid Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) PROTECT Rare Act (H.R. 6094) MVP Act (H.R. 2666)
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2023 · fourth_quarter · Medicare/Medicaid
Coverage of blood transfusions under Medicare Hospice Benefit Issues related to CAR-T/cellular and gene therapies Implementation of the Medicare Access and CHIP Reauthorization Act pf 2015 (P.L. 114-10) Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) CMS national coverage determinations Medicaid coverage for sickle cell disease Issues impacting opioid access/use for patients with hematologic disease and disorders Issues related to telemedicine/telehealth Sickle cell disease/trait issues, including coverage for cell and gene therapies Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Strengthening Medicare for Patients and Providers Act (H.R. 2474) Resident Physician Shortage Reduction Act (S. 1302) CONNECT for Health Act (S. 2016/ H.R. 4189) Improving Access to Transfusion Care for Hospice Patients Act (S. 2186) Provider Reimbursement Stability Act of 2023 (H.R. 6371) Establishment of Disincentives for Health Care Providers That Have Committed Information Blocking proposed rule (RIN 0955-AA05)
Client expense: $30,000 · Firm income: Not reported
2023 · fourth_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423/H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039/H.R. 6301) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297) Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746)
Client expense: $30,000 · Firm income: Not reported
2023 · third_quarter · Medicare/Medicaid
Reimbursement for hemophilia services and treatments in Medicare Reimbursement for hemophilia services and treatments in Medicaid Implementation of the Hemophilia SNF Access Act Coverage for Telehealth Services Closing the Medicaid coverage gap Issues related to 1115 Waivers in Medicaid Medicaid unwinding, the process for redetermination of Medicaid eligibility Preserving and expanding access to Medicaid Comments in response to the Medicare CY24 Physician Fee Schedule Proposed Rule Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996)
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Medicare/Medicaid
Comments in response to the Medicare CY24 Physician Fee Schedule Proposed Rule Engagement with the Center for Medicare and Medicaid Innovation on the Cell & Gene Therapy Access Model Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996) CMSs Office of Minority Health Sickle Cell Disease Action Plan
Client expense: Not reported · Firm income: $20,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · third_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423 / H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages House discussion Draft of Stop Drug Shortages Act
Client expense: $30,000 · Firm income: Not reported
2023 · second_quarter · Health Issues
S 996/ HR 1672 Sickle Cell Disease Comprehensive Care Act; HR 3884, Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2023
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce Sickle Cell Care Expansion Act (S. 1423 / H.R. 3100) Life Saving Leave Act (H.R. 3024) Cancer Drug Parity Act (S. 2039) Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884) Issues impacting drug shortages
Client expense: $30,000 · Firm income: Not reported
2023 · first_quarter · Health Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) Hematology/oncology drug research and approval issues Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144) Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Issues related to CAR-T/cellular and gene therapies Issues impacting opioid access/use for patients with hematologic disease and disorders Issues impacting blood supply shortages/safety Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S. 996) Issues related to maternal health care and abortion access Issues related to healthcare workforce
Client expense: $30,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
| Democratic |
| LA |
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE